Faster cognitive decline in dementia due to Alzheimer disease with clinically undiagnosed Lewy body disease
Beach, Thomas G
Adler, Charles H
Sabbagh, Marwan N
Shill, Holly A
Jacobson, Sandra A
Belden, Christine M
Caselli, Richard J
Woodruff, Brian K
Rapscak, Steven Z
Ahern, Geoffrey L
Caviness, John N
Mehta, Shyamal H
Shprecher, David R
Spann, Bryan M
Davis, Kathryn J
Long, Kathy E
Nicholson, Lisa R
Glass, Michael J
Walker, Jessica E
Walker, Douglas G
Serrano, Geidy E
Sue, Lucia I
Reiman, Eric M
AffiliationUniv Arizona, Dept Neurol
Univ Arizona, Coll Med Phoenix
MetadataShow full item record
PublisherPUBLIC LIBRARY SCIENCE
CitationMalek-Ahmadi M, Beach TG, Zamrini E, Adler CH, Sabbagh MN, Shill HA, et al. (2019) Faster cognitive decline in dementia due to Alzheimer's disease with clinically undiagnosed Lewy body disease. PLoS ONE 14(6): e0217566. https://doi.org/10.1371/journal.pone.0217566
RightsCopyright © 2019 Malek-Ahmadi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at firstname.lastname@example.org.
AbstractBackground Neuropathology has demonstrated a high rate of comorbid pathology in dementia due to Alzheimer's disease (ADD). The most common major comorbidity is Lewy body disease (LBD), either as dementia with Lewy bodies (AD-DLB) or Alzheimer's disease with Lewy bodies (AD-LB), the latter representing subjects with ADD and LBD not meeting neuropathological distribution and density thresholds for DLB. Although it has been established that ADD subjects with undifferentiated LBD have a more rapid cognitive decline than those with ADD alone, it is still unknown whether AD-LB subjects, who represent the majority of LBD and approximately one-third of all those with ADD, have a different clinical course. Methods Subjects with dementia included those with "pure" ADD (n = 137), AD-DLB (n = 64) and ADLB (n = 114), all with two or more complete Mini Mental State Examinations (MMSE) and a full neuropathological examination. Results Linear mixed models assessing MMSE change showed that the AD-LB group had significantly greater decline compared to the ADD group (beta = -0.69, 95% CI: -1.05, -0.33, p<0.001) while the AD-DLB group did not (beta = -0.30, 95% CI: -0.73, 0.14, p = 0.18). Of those with AD-DLB and AD-LB, only 66% and 2.1%, respectively, had been diagnosed with LBD at any point during their clinical course. Compared with clinically-diagnosed AD-DLB subjects, those that were clinically undetected had significantly lower prevalences of parkinsonism (p = 0.046), visual hallucinations (p = 0.0008) and dream enactment behavior (0.013). Conclusions The probable cause of LBD clinical detection failure is the lack of a sufficient set of characteristic core clinical features. Core DLB clinical features were not more common in AD-LB as compared to ADD. Clinical identification of ADD with LBD would allow stratified analyses of ADD clinical trials, potentially improving the probability of trial success.
NoteOpen access journal
VersionFinal published version
SponsorsNational Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U24 NS072026]; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG19610]; Arizona Department of Health Services ; Arizona Biomedical Research Commission [4001, 0011, 05-901, 1001]; Michael J. Fox Foundation for Parkinson's Research; Shanghai Green Valley Pharmaceutical
Except where otherwise noted, this item's license is described as Copyright © 2019 Malek-Ahmadi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License.
- Severe hyposmia distinguishes neuropathologically confirmed dementia with Lewy bodies from Alzheimer's disease dementia.
- Authors: Beach TG, Adler CH, Zhang N, Serrano GE, Sue LI, Driver-Dunckley E, Mehta SH, Zamrini EE, Sabbagh MN, Shill HA, Belden CM, Shprecher DR, Caselli RJ, Reiman EM, Davis KJ, Long KE, Nicholson LR, Intorcia AJ, Glass MJ, Walker JE, Callan MM, Oliver JC, Arce R, Gerkin RC
- Issue date: 2020
- Phenotypic differences based on staging of Alzheimer's neuropathology in autopsy-confirmed dementia with Lewy bodies.
- Authors: Peavy GM, Edland SD, Toole BM, Hansen LA, Galasko DR, Mayo AM
- Issue date: 2016 Oct
- Apathy is associated with faster global cognitive decline and early nursing home admission in dementia with Lewy bodies.
- Authors: Breitve MH, Brønnick K, Chwiszczuk LJ, Hynninen MJ, Aarsland D, Rongve A
- Issue date: 2018 Aug 18
- Homovanillic acid and 5-hydroxyindole acetic acid as biomarkers for dementia with Lewy bodies and coincident Alzheimer's disease: An autopsy-confirmed study.
- Authors: Morimoto S, Takao M, Hatsuta H, Nishina Y, Komiya T, Sengoku R, Nakano Y, Uchino A, Sumikura H, Saito Y, Kanemaru K, Murayama S
- Issue date: 2017
- Anxiety symptoms are quantitatively and qualitatively different in dementia with Lewy bodies than in Alzheimer's disease in the years preceding clinical diagnosis.
- Authors: Segers K, Benoit F, Meyts JM, Surquin M
- Issue date: 2020 May